• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Radoff-JEC Group Announces ISS’ Support of its Case for Change at Seer, Inc.

    7/17/26 8:20:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email

    ISS Recommends Stockholders Vote FOR Radoff-JEC Group Nominees Howard H. Berman and Luis E. Rinaldini, WITHHOLD Support on Seer Directors Terrance McGuire, Dipchand Nishar and Nicolas Roelofs and Vote AGAINST the NOL Pill

    Concludes That the Board’s Actions "[Raise] Questions About the Ability of the Board to Exercise Independent Oversight" of Chairman and CEO Omid Farokhzad, M.D.

    Radoff-JEC Group Urges Stockholders to Vote on the WHITE Proxy Card to Elect All Three of its Independent, Qualified Nominees

    Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of Seer, Inc.’s (NASDAQ:SEER) ("Seer" or the "Company") outstanding common stock, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that the Company’s stockholders vote on the WHITE proxy card FOR the election of Howard H. Berman, Ph.D. and Luis E. Rinaldini to Seer’s Board of Directors (the "Board").

    ISS also recommends stockholders WITHHOLD support from incumbent directors Terrance McGuire, Dipchand Nishar, as well as Nominating and Governance Committee Chair Nicolas Roelofs, Ph.D., and vote AGAINST the ratification of the NOL pill.

    In its report, ISS affirmed the Radoff-JEC Group’s case for urgent boardroom change, stating:1

    • "The company has lost over 95 percent of its market cap since completing its IPO in late 2020, and there is no convincing indication that a reversal of fortune lies ahead."
    • "Revenue growth has been muted, operating expenses have remained elevated, and management has forecast that profitability will not be achieved before 2031. In other words, despite past investments and messaging, the company has failed to reach the inflection point necessary for commercial viability."
    • "There is little evidence to suggest that a meaningful turnaround is imminent, while the company's corporate governance practices have not consistently aligned with shareholders' best interest."
    • "A number of directors have professional, business, or personal relationships with Farokhzad and amongst themselves that extend beyond their service at the company, raising questions about the ability of the board to exercise independent oversight."
    • "Ultimately, the board is presenting shareholders with an account that is not supported by the facts."

    ISS also highlighted Seer’s contradictory statements and posture toward our acquisition proposals as compared to Chairman and CEO Omid Farokhzad, M.D.’s offer:

    • "Interestingly, the headline cash value of [Farokhzad’s] offer also falls materially below the company's net cash and investments; a criticism the board previously levied at the dissidents' offers."
    • "While Farokhzad has articulated his own reasons for pursuing a take-private, the offer does more to validate the dissidents' concerns regarding public company viability than it does to support the board's messaging to shareholders in this contest."
    • "The board has emphasized the company's long-term prospects and purported proximity to inflection, while casting the dissident acquisition proposals as a short-sighted gambit to raid the company's balance sheet. At the same time, the terms and timing of Farokhzad's proposal to take the company private does little to convey confidence in the story being told."

    The Radoff-JEC Group issued the following statement:

    "The ISS report is a scathing indictment of how Chairman and CEO Farokhzad and his friends have seemingly failed to manage Seer in the best interests of all stockholders, highlighting the Company’s massive value destruction since its IPO and lack of a viable future in the public market. ISS also saw through the Board’s attempts to pull the wool over long-suffering investors’ eyes by making clearly unsupported and misleading statements about its awful track record and about our campaign to prevent further losses.

    We are confident that our fellow stockholders will make their feelings known at the ballot box ahead of the July 28th annual meeting. We believe electing all three of our independent nominees – Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini – is the most effective path to strengthening oversight and ensuring the Board runs an objective strategic review process aimed at maximizing value for all Seer stockholders."

    ***

    Vote FOR the Radoff-JEC Group’s Nominees – Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini – Today to Support a Credible Strategic Review Process Aimed at Maximizing Value for ALL Seer Stockholders

    Do NOT Vote for Omid Farokhzad, M.D., Terrance McGuire or Dipchand (Deep) Nishar

    Questions about how to vote? Contact (888) 368-0379 or info@saratogaproxy.com.

    Visit www.SaratogaProxy.com/SEER to learn more.

    ____________________

    1 Permission to quote ISS was neither sought nor received.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260716968648/en/

    Greg Lempel

    greg@fondrenlp.com

    or

    Saratoga Proxy Consulting LLC

    John Ferguson / Joseph Mills, 212-257-1311

    info@saratogaproxy.com

    Get the next $SEER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    5/4/2026$4.00Buy
    Canaccord Genuity
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nishar Dipchand sold $23,265 worth of shares (10,660 units at $2.18) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 59,044 units (SEC Form 4) to cover withholding tax

    4 - Seer, Inc. (0001726445) (Issuer)

    7/10/26 6:23:12 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CFO Horn David R. sold $12,352 worth of shares (7,303 units at $1.69), decreasing direct ownership by 1% to 493,959 units (SEC Form 4) (tax liability)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/21/26 5:12:54 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Commercial Officer Bazarko Anthony R. was granted 75,000 shares (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/11/26 6:20:12 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seer Urges Stockholders to Vote “FOR” Seer’s Highly Qualified Director Nominees on the BLUE Proxy Card TODAY

    2026 Annual Meeting of Stockholders To Be Held July 28, 2026 Seer’s Board of Directors is Highly Engaged, Independent and Purpose-Built to Oversee Strategic Execution at This Critical Time Radoff-JEC Group’s Nominees Lack Qualifications, Expertise and Independence Necessary to Add Value to Board REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company") today issued a letter to stockholders reminding them to vote their shares ahead of the Company’s upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting"), scheduled to be held on July 28, 2026 at 1:30 p.m. Pacific Time. Stockholders as of May 29, 2026 are entitled to vote at the

    7/20/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

    REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors, consisting of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected the unsolicited, non-binding proposal received on July 1, 2026, from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights (the "Proposal"). Consistent with its fiduciary duties, the Special C

    7/20/26 6:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Radoff-JEC Group Announces ISS’ Support of its Case for Change at Seer, Inc.

    ISS Recommends Stockholders Vote FOR Radoff-JEC Group Nominees Howard H. Berman and Luis E. Rinaldini, WITHHOLD Support on Seer Directors Terrance McGuire, Dipchand Nishar and Nicolas Roelofs and Vote AGAINST the NOL Pill Concludes That the Board’s Actions "[Raise] Questions About the Ability of the Board to Exercise Independent Oversight" of Chairman and CEO Omid Farokhzad, M.D. Radoff-JEC Group Urges Stockholders to Vote on the WHITE Proxy Card to Elect All Three of its Independent, Qualified Nominees Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of Seer, Inc.’s (NASDAQ:SEER) (

    7/17/26 8:20:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    7/20/26 4:10:47 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Seer Inc.

    8-K - Seer, Inc. (0001726445) (Filer)

    7/20/26 4:08:49 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    7/20/26 8:03:56 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Seer with a new price target

    Canaccord Genuity initiated coverage of Seer with a rating of Buy and set a new price target of $4.00

    5/4/26 8:35:45 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Board of Directors Issues Letter to Shareholders Highlighting the Company's Significant Scientific Progress and Addressing Radoff and Torok's Short-Sighted Campaign

    REDWOOD CITY, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company") today issued a letter to stockholders containing important information for shareholders to consider in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders as of May 29, 2026 will be entitled to vote at the Annual Meeting. The Board recommends that stockholders vote "FOR" the election of Seer's seven highly qualified nominees on the BLUE proxy card. The full text of the letter follows: Dear Fellow Seer Stockholders, You have an important choice to make regarding the future of Seer at our upcoming Ann

    6/15/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

    Reinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Undermines Stockholder Value Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders of record as of

    6/3/26 6:00:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

    REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026. Recent Highlights Achieved revenue of $2.8 million in the first quarter of 2026Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer's platformSecured a collaboration with Precision Health Research, Singapore to provide deep, unbiased proteomics on 10,000 samples for their PRECISE-SG100K study, a landmark multi-ancestry, population-scale cohort of approximately 100,000 Singapo

    5/13/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer

    Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer's Proteograph® Product Suite REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced the appointment of Anthony Bazarko as Chief Commercial Officer. Mr. Bazarko brings more than two decades of commercial leadership experience across the life sciences, diagnostics, and biotechnology industries, with a demonstrated track record of driving revenue growth, building high-performing teams, and leading global go-to-market strategies. Mr. Bazarko joins Seer from

    5/4/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials